Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and Δ9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor Symptoms.
Christopher H DomenStefan SillauYing LiuMichelle AdkinsSarah RajkovicJacquelyn BainbridgeCristina SempioJost KlawitterMaureen A LeeheyPublished in: Movement disorders : official journal of the Movement Disorder Society (2023)
Data suggest this CBD/THC drug has a small detrimental effect on cognition following acute/short-term use in PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Keyphrases
- placebo controlled
- double blind
- drug induced
- electronic health record
- clinical trial
- big data
- study protocol
- phase ii
- liver failure
- phase iii
- squamous cell carcinoma
- mild cognitive impairment
- emergency department
- sleep quality
- respiratory failure
- deep learning
- extracorporeal membrane oxygenation
- acute respiratory distress syndrome
- meta analyses